Does a GLP-1 improve insulin resistance in perimenopause?
# Does a GLP-1 improve insulin resistance in perimenopause?
Key takeaways
Dr. Linda's take
A woman in her mid-forties will tell me the same thing a dozen different ways: the eating has not really changed, but the middle has, and the labs her doctor used to wave off are starting to drift. She is often describing insulin resistance, and she is not imagining the timing.
Perimenopause is a genuine metabolic shift, not a willpower failure, and it deserves an honest answer about what a medication can and cannot do about it. Below I separate two things: what the transition does to insulin and fat, which is well described, and whether these medicines meaningfully move insulin resistance, which has real data alongside an honest asterisk about who was actually studied. If you want a starting point for whether any of this fits your situation, our eligibility quiz is one place to begin, though it is general education and not a plan for you specifically.
Why does perimenopause raise insulin resistance?
The pattern shows up in the research, not just in the exam room. The incidence of many metabolic conditions increases after the menopause, a time when insulin resistance also increases. Insulin resistance travels with a cluster of metabolic problems, including glucose intolerance, dyslipidemia, and central obesity, that predispose to cardiovascular disease and diabetes.
That combination is a big reason the same portions and the same workouts that held your weight steady in your thirties can quietly stop working in your forties. The target has moved, and the drift toward insulin resistance is part of the change. We also cover why weight medicines can work more slowly in perimenopause if that is the part you are living right now.
What happens to visceral fat during perimenopause?
Insulin resistance and belly fat are not separate stories in midlife; they move together. During perimenopause, even with only minimal-to-modest weight gain, women experience an expansion of visceral adipose tissue, alongside a reduction in gluteofemoral subcutaneous fat. This pattern of fat redistribution is associated with a greater prevalence of cardiovascular disease risk factors and a higher incidence of cardiovascular disease events.
Longer-term data point the same way. Visceral fat increases with the menopause and is an independent predictor of the metabolic syndrome, diabetes, and cardiovascular disease in women. Visceral fat is the metabolically active depot, so its expansion is exactly the change that feeds insulin resistance and cardiometabolic risk, which is why the scale alone can mislead you here. There is more on that in how these medicines affect perimenopause belly fat.
Can a GLP-1 improve insulin resistance?
Here is where the medication data enter, and they are genuinely encouraging. GLP-1 medicines such as semaglutide stimulate insulin secretion and reduce glucagon secretion in a glucose-dependent manner. In a meta-analysis of adults, semaglutide reduced insulin resistance (HOMA-IR ratio 0.82) and appeared to improve insulin sensitivity compared with placebo or active comparators.
Read that as a direction of travel rather than a guarantee for any one person. The mechanism nudges the insulin system in the helpful direction, and the pooled trial data show insulin resistance easing, which is precisely the metabolic problem that perimenopause tends to worsen.
Does a GLP-1 reduce the visceral fat that drives it?
Insulin resistance in midlife is tightly linked to the deep abdominal fat, so a fair question is whether these medicines touch that depot. They do. This liraglutide trial was conducted in a group that was 92% female participants, which is unusually relevant for a question about women. In that trial, visceral fat fell by 12.49% over a median of 36 weeks with liraglutide, compared with 1.63% with placebo.
Weight comes down alongside the fat. In the STEP 1 trial, once-weekly semaglutide at 2.4 mg reduced body weight by 14.9% from baseline over 68 weeks, compared with 2.4% in the placebo group. Losing that deep abdominal fat is one of the plausible routes by which these medicines ease the insulin resistance that builds during the transition.
How much of this applies specifically to perimenopause?
This is the asterisk I promised. Most of these trials enrolled broad groups of adults with excess weight, not women selected for the menopause transition, so the insulin and visceral-fat findings describe a general effect rather than one isolated to perimenopausal women. That does not make them irrelevant to you; it means the honest framing is a well-supported general benefit that overlaps neatly with the perimenopausal problem, not a study that proved the point in perimenopausal women specifically.
Timing, other medications, and your own risk picture all matter, which is a conversation for a licensed clinician. If starting is the question on your mind, we walk through whether it is safe to start a weight medication during perimenopause separately.
Frequently asked questions
Does perimenopause itself make insulin resistance worse?
Broadly, yes. The incidence of many metabolic conditions increases after the menopause, a time when insulin resistance also increases, and it clusters with central weight gain rather than arriving alone.
Does a GLP-1 actually lower insulin resistance?
The data lean that way. In a meta-analysis of adults, semaglutide reduced insulin resistance (HOMA-IR ratio 0.82) compared with placebo or active comparators. That is a pooled average across trials, not a promise about any single person.
Will a GLP-1 shrink perimenopausal belly fat?
It reduces visceral fat, though not the belly on its own. In a trial that was 92% female participants, visceral fat fell by 12.49% over a median of 36 weeks with liraglutide, compared with 1.63% with placebo, as part of whole-body fat loss rather than spot treatment.
Were these medicines studied in perimenopausal women specifically?
Mostly no. The insulin and visceral-fat trials enrolled broad groups of adults with excess weight, so they describe a general effect that overlaps with the perimenopausal reality rather than a perimenopause-specific result.
References
1. Whitcroft S, Herriot A. Insulin resistance and management of the menopause: a clinical hypothesis in practice. Menopause International (2011). PubMed PMID 21427422. https://pubmed.ncbi.nlm.nih.gov/21427422/ (Accessed 2026-07-27).
2. Manning ME, Stockman SL, Zanni MV. Perimenopause as an obesogenic sensitive period: Contributions to elevated cardiovascular risk. American Journal of Preventive Cardiology (2026). PubMed PMID 41567597. https://pubmed.ncbi.nlm.nih.gov/41567597/ (Accessed 2026-07-27).
3. Janssen I, Powell LH, Kazlauskaite R, Dugan SA. Testosterone and visceral fat in midlife women: the Study of Women's Health Across the Nation (SWAN) fat patterning study. Obesity (Silver Spring) (2010). PubMed PMID 19696765. https://pubmed.ncbi.nlm.nih.gov/19696765/ (Accessed 2026-07-27).
4. WEGOVY (semaglutide) injection, prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b (Accessed 2026-07-27).
5. Abusedera O, Sherif J, Smida M, Fredericks S. The Effect of Semaglutide on Pancreatic beta-Cell Function in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine (2025). PubMed PMID 41464636. https://pubmed.ncbi.nlm.nih.gov/41464636/ (Accessed 2026-07-27).
6. Neeland IJ, Marso SP, Ayers CR, et al. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Diabetes & Endocrinology (2021). PubMed PMID 34358471. https://pubmed.ncbi.nlm.nih.gov/34358471/ (Accessed 2026-07-27).
7. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine (2021). PubMed PMID 33567185. https://pubmed.ncbi.nlm.nih.gov/33567185/ (Accessed 2026-07-27).
---
*This article is general education and is not medical advice. It cannot tell you what is right for your body. Talk with a licensed clinician about your own situation.*
*Written and clinically reviewed by Dr. Linda Moleon, MD. Last reviewed 2026-07-27.*
Keep reading
Can a GLP-1 ease knee pain after menopause?
Knee pain often worsens after menopause. Dr. Linda Moleon, MD reviews what a major trial found on GLP-1 weight loss and knee osteoarthritis.
Do Black and Latina women need a different GLP-1 dose?
GLP-1 dosing is the same regardless of race or ethnicity. Dr. Linda Moleon, MD explains what the labels and trial subgroup data show.
Does a GLP-1 improve fatty liver in women with PCOS?
PCOS and fatty liver are linked through insulin resistance. Dr. Linda Moleon, MD looks at what GLP-1 medicines may do for liver health in PCOS.
Does Florida heat raise your risk of dehydration on a GLP-1?
Florida heat and GLP-1 stomach side effects can both drain fluid. Dr. Linda Moleon, MD explains dehydration signs and when to call a clinician.
Does a GLP-1 lower blood sugar after menopause?
After menopause, insulin resistance tends to rise. Dr. Linda Moleon, MD explains how GLP-1 medicines lower blood sugar and what that means for postmenopausal women.
Are Black and Latina women more likely to stop a GLP-1 early?
Black and Latina women face real gaps in staying on GLP-1 care. Dr. Linda Moleon, MD on what the data show and the structural reasons behind early discontinuation.